
Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: May 8th 2013 | Updated: